Citadel Advisors
QNTM

Citadel Advisors’s Quantum Biopharma Class B Subordinate Voting Shares QNTM Stock Holding History

Citadel Advisors’s Portfolio QNTM Stock Details QNTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-23
Closed -$1.07K – 15624
2024
Q1 		$1.07K Buy
23
+14
+156% +$767 ﹤0.01% 14187
2023
Q4 		$552 Sell
9
-8
-47% -$563 ﹤0.01% 14007
2023
Q3 		$1.33K Sell
17
-29
-63% -$2.37K ﹤0.01% 13884
2023
Q2 		$3.45K Sell
46
-28
-38% -$2.4K ﹤0.01% 13691
2023
Q1 		$7.44K Sell
74
-32
-30% -$2.75K ﹤0.01% 13721
2022
Q4 		$5.44K Buy
+106
New +$5.87K ﹤0.01% 13998
2022
Q3 		– Sell
-183
Closed -$9K – 13780
2022
Q2 		$9K Sell
183
-28
-13% -$1.68K ﹤0.01% 12611
2022
Q1 		$12K Sell
211
-117
-36% -$7.08K ﹤0.01% 13364
2021
Q4 		$22K Sell
328
-307
-48% -$26.6K ﹤0.01% 13567
2021
Q3 		$65K Sell
635
-422
-40% -$45.1K ﹤0.01% 13212
2021
Q2 		$120K Sell
1,057
-85
-7% -$9.86K ﹤0.01% 12745
2021
Q1 		$142K Buy
+1,142
New +$160K ﹤0.01% 12117

Other funds holding QNTM

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PTP
Platform Technology Partners New York $611M AUM 25.5% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AUB
Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

Citadel Advisors's QNTM Position: Q1 2026 in Review

Citadel Advisors held its Quantum Biopharma Class B Subordinate Voting Shares (QNTM) position steady in Q1 2026 at 15,863 shares worth $76.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12205.

Citadel Advisors first reported a position in QNTM in Q4 2020 and has held it in 10 quarters since. The position peaked at $154K in Q2 2021. 25 funds tracked by Wall St. Rank hold QNTM as of Q1 2026.

  • Citadel Advisors held 15,863 shares of Quantum Biopharma Class B Subordinate Voting Shares worth $76.6K as of Q1 2026.
  • Citadel Advisors left its Quantum Biopharma Class B Subordinate Voting Shares share count unchanged in Q1 2026.
  • Quantum Biopharma Class B Subordinate Voting Shares made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12205 holding.
  • Citadel Advisors first reported a position in Quantum Biopharma Class B Subordinate Voting Shares in Q4 2020 and has held it in 10 quarters since.
  • Citadel Advisors's Quantum Biopharma Class B Subordinate Voting Shares position peaked at $154K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Quantum Biopharma Class B Subordinate Voting Shares as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.